NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment

The BIRD Foundation has Approved an Additional Payment to Kadimastem and Miami Based iTolerance Inc. from the Total Grant for the Continued Co-Development of the Innovative Treatment for Diabetes

Vote of Confidence by Major Kadimastem Shareholder in the Merger Transaction with Swiss Biopharma Company NLS Pharmaceutics

NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement

Kadimastem completes another stage towards the merger with NLS Pharmaceutics, which has Regained Full Compliance with Nasdaq Listing Requirements

Kadimastem Ltd. and NLS Pharmaceutics Announce Binding Term Sheet to Merge

The World Prestigious Diabetes Research Institute, University of Miami, Announces Kadimastem's Joint Project as Breakthrough Transplantation Approach for the Treatment of Type 1 Diabetes

Kadimastem Takes Another Step Towards Signing the Merger Agreement with Nasdaq Listed IMCC

Kadimastem advances towards Nasdaq: Company Signs a Memorandum of Understanding to Merge with a Company traded on the Nasdaq

Kadimastem Receives Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes in India

A peer reviewed article on Kadimastem's AstroRx® Cryopreserved off the Shelf Cell Product for the Treatment of ALS was Published in the Journal of Clinical Toxicology

Kadimastem and iTolerance Complete Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting with the U.S. FDA

Kadimastem and iTolerance Submit INTERACT Request with FDA for Potential Cure for Type 1 Diabetes

Kadimastem Receives US Patent for Its Cell Selection & Enrichment Technology Used to Develop IsletRx

Kadimastem Granted European Patent for Its IsletRx Treatment for Diabetes

Kadimastem and iTolerance Sign Agreement and Receive US$1 Million from BIRD Foundation

Kadimastem Earns FDA IND Approval For its US Phase IIa Clinical Trial with AstroRx® to Treat ALS

Kadimastem Submits IND Application to the FDA for its Phase IIa Clinical Trial with AstroRx® for ALS

Kadimastem's Clinical Trial in ALS Patients was Publicized in the Journal of Translational Medicine

Awarded Patent in Australia for its AstroRx® Technology for the Treatment of ALS and Drug Screening